JPS63188607A - Cosmetic - Google Patents
CosmeticInfo
- Publication number
- JPS63188607A JPS63188607A JP1908787A JP1908787A JPS63188607A JP S63188607 A JPS63188607 A JP S63188607A JP 1908787 A JP1908787 A JP 1908787A JP 1908787 A JP1908787 A JP 1908787A JP S63188607 A JPS63188607 A JP S63188607A
- Authority
- JP
- Japan
- Prior art keywords
- water
- extracts
- soluble protein
- skin
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 241000283690 Bos taurus Species 0.000 claims abstract description 24
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 210000000481 breast Anatomy 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 239000012888 bovine serum Substances 0.000 claims abstract description 6
- 210000000952 spleen Anatomy 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 150000007513 acids Chemical class 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 17
- 210000003491 skin Anatomy 0.000 abstract description 14
- 210000001541 thymus gland Anatomy 0.000 abstract description 8
- 210000002615 epidermis Anatomy 0.000 abstract description 6
- 238000002523 gelfiltration Methods 0.000 abstract description 5
- 238000005194 fractionation Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 abstract description 3
- 239000002932 luster Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000005185 salting out Methods 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000001557 animal structure Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000201841 Celosia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔イ〕 発明の目的
本発明は、牛の血清(血液)、又−は牛の各種の臓器(
乳房、肺臓、胸腺)から、有機溶媒、強酸、強アルカリ
、酵素(蛋白分解酵素類)を用いず抽出された、水溶性
蛋白を含有する、新規化粧料に関する。[Detailed Description of the Invention] [A] Purpose of the Invention The present invention is directed to the use of bovine serum (blood) or various bovine organs (
The present invention relates to a new cosmetic containing water-soluble protein extracted from the breast, lung, thymus) without using organic solvents, strong acids, strong alkalis, or enzymes (proteolytic enzymes).
「産業上の利用分野j
本発明は、牛の血清、又は牛の各種臓器から抽出された
、特定された分子量と等電点によって示される水溶性蛋
白質を含有する化粧料にあるが、ここで示きれる、水溶
性蛋白質は、繊維芽細胞に対して直接的に作用し、その
細胞を賦活させ、皮膚の老化を防ぎ、外傷又は、火傷に
あっては、肉芽組織の再生に働き、表皮にクレータ−状
の傷あとを少なくし、表皮(肌)を滑らかとなす、よっ
て、皮膚外用塗布による治療用剤としても用いることが
出来る。"Industrial Application Field: The present invention relates to a cosmetic containing a water-soluble protein extracted from bovine serum or various bovine organs and having a specified molecular weight and isoelectric point. Water-soluble proteins act directly on fibroblasts, activate them, prevent skin aging, and in the case of trauma or burns, work to regenerate granulation tissue and stimulate the epidermis. It reduces crater-like scars and makes the epidermis (skin) smooth, so it can also be used as a therapeutic agent applied externally to the skin.
又、本発明においては、用いる原料について、牛の血清
(血液)、乳房、肺臓、胸腺をもとに示すも、本発明に
示す抽出手段を採用すれば、その他の家畜M(動物)、
例えば豚などの各種臓器や血清(血液)を用いて得られ
たものも、利用出来る。In addition, in the present invention, although the raw materials to be used are shown based on bovine serum (blood), breast, lung, and thymus gland, if the extraction means shown in the present invention is adopted, other livestock M (animals),
For example, those obtained using various organs such as pigs and serum (blood) can also be used.
1従来の技術」
古来から、家畜M等の動物の血液や臓器をも七に抽出さ
れたエキス類が、化粧料や医薬品に用いられてきていた
。これらの抽出物(エキス)に関する効能又は効果(作
用)については、細胞賦活剤又は、組織再生修復作用を
もった因子が含まれていると言われており、例えば、胎
盤、肝、腎、牌、心、胃及び腸などの臓器、さらに血液
から、種々の方法で得られた抽出物が応用きれてきた。1. Prior art Since ancient times, extracts made from the blood and organs of animals such as livestock have been used in cosmetics and medicines. Regarding the efficacy or effect (action) of these extracts, it is said that they contain factors that have cell activators or tissue regeneration and repair effects, such as placenta, liver, kidney, and tablets. Extracts obtained by various methods from organs such as the heart, stomach, and intestines, as well as blood, have been successfully applied.
しかし、従来、細胞賦活、又は組織再生修復作用をもっ
た主役成分について、特定きれることはなく、不明な部
分が多かった。However, until now, it has not been possible to identify the main component that has cell activation or tissue regeneration and repair effects, and much remains unclear.
なかでも水溶性蛋白質、あるいは水溶性ペブデド、核酸
又は核#関連物質部を含む水溶性エキス類は、化粧料等
に繁用されており、これらのエキス中に含まれる水溶性
物質が、細胞賦活、又は組織再生促進作用を示すものと
推定されてきた。Among them, water-soluble extracts containing water-soluble proteins, water-soluble peptides, nucleic acids, or nuclear #related substances are frequently used in cosmetics, etc., and the water-soluble substances contained in these extracts are effective for cell activation. It has been presumed that it exhibits a tissue regeneration-promoting effect.
すなわち、これらの推定は、細胞や組織中に分布する成
分を分析することによって、その有力因子の一つと考え
られてきたわけである。In other words, these estimates have been made by analyzing components distributed in cells and tissues, and have been considered to be one of the leading factors.
ところが、これらの従来から知られてきた抽出物から、
水溶性成分を含むエキスについて、真に細胞に対して、
直接に賦活作用を有するものとなると、それを立証した
抽出物は、きわめて少ないのが現況であった。However, from these conventionally known extracts,
Regarding extracts containing water-soluble components, they are truly effective for cells.
At present, there are very few extracts that have been proven to have a direct activating effect.
そこで本発明者らは、古来から用いられてきた、牛等の
動物臓器由来の抽出物に関する、細胞や組織の賦活、再
生修復能を求め、再評価し、さらに優れた抽出物を開発
することをテーマとなし、細胞レベルから直接的に評価
する試験法の確立に当り、後記の方法を開発するに至っ
た。そして、すでに本発明者らは、この新しい評価法で
ある、培養繊維芽細胞をもとに行う手段を採用して、そ
れに対する成長(増M)作用から、定量的な評価をもっ
て、牛又はヒトの正常分娩後の胎盤中から、強力な賦活
(成長)因子として、例えば牛の胎盤からは、水溶性の
蛋白であり、その分子量が80.000 (停電点6.
5〜7.0)、及び分子量が25.000(等電点5.
0〜5.5 ’) テある物質の単離に成功し、昭和6
0年特許願第159713号をもって出願した。Therefore, the present inventors sought and reevaluated the cell and tissue activation and regeneration and repair abilities of extracts derived from animal organs such as cows that have been used since ancient times, and developed even better extracts. In order to establish a test method for direct evaluation from the cellular level, we developed the method described below. The present inventors have already employed this new evaluation method, which is based on cultured fibroblasts, to quantitatively evaluate the growth (M increase) effect on the fibroblasts in cattle or humans. For example, from the placenta of cows, it is a water-soluble protein with a molecular weight of 80,000 (power cutoff point 6.
5-7.0), and the molecular weight is 25.000 (isoelectric point 5.000).
0 to 5.5') succeeded in isolating a certain substance, and in 1932
The application was filed with Patent Application No. 159713.
1発明が解決しようとする問題点」
本発明者らは、引き続き各種動物臓器由来の抽出物につ
いて、再評価を続けてきた。すなわち、前記したごとく
、動物由来の抽出物が古くから、細胞賦活能や、組織賦
活能が有ると言われながらも、実際にm胞に対して直接
的賦活作用を有する抽出物となると、ことごと〈従来法
による抽出手段を用いて得られてものは、細胞に対して
増殖能はゼロか、又は極めて弱いものであることがわか
ったのである。1. Problems to be Solved by the Invention The present inventors have continued to re-evaluate extracts derived from various animal organs. In other words, as mentioned above, although animal-derived extracts have long been said to have cell-activating and tissue-activating abilities, when it comes to extracts that actually have a direct activating effect on m-cells, It has been found that those obtained using conventional extraction methods have zero or very weak ability to proliferate cells.
すなわち、各臓器体には、細胞に直接的に賦活作用を有
し、増殖能を示す物質は存在するも、抽出法が不完全で
あり、その結果は、まったく、作用を有さない成分を含
むような抽出物が、用いられてきたとも推定されたので
ある。ここでは、各種臓器を入手し、直接的に細胞に生
理活性能を有する物質を求めることにテーマを集中して
開発に当ったわけである。In other words, although there are substances in each organ that have a direct activating effect on cells and exhibit proliferation ability, the extraction method is incomplete, and as a result, only components that have no effect are extracted. It is also assumed that extracts that contain these substances have been used. Here, we focused our development efforts on obtaining various organs and directly searching for substances that have physiological activity in cells.
「評価法。“Evaluation method.
皮膚の主な細胞には、表皮細胞(ケラチノサイト)、繊
維芽細胞があるが、例えば、モルモット(ハートレー系
)から採取した繊維芽細胞は、5%FBSを添加したイ
ーグルのMEMum中で、盛んに分裂増殖し、その倍数
増殖時間は第1図に示すごとく、約48時間である。The main cells of the skin include epidermal cells (keratinocytes) and fibroblasts. For example, fibroblasts collected from guinea pigs (Hartley strain) flourish in Eagle's MEMum supplemented with 5% FBS. The cells undergo division and proliferation, and the time for multiple proliferation is approximately 48 hours, as shown in FIG.
細胞増殖率の瀾定法は、まず、直径3.5Offlのベ
トリディッシ、(フーニング社製)に、1−当り4〜5
X 10’個の細胞を植え、低濃度のFBSを添加し
た、イーグルのMEM培地を2〜3日目ごとに交換する
。細胞数は、2〜3日目ごとにビュルケルチュルクの血
球計算盤を用いて測定する。To determine the cell proliferation rate, first, 4 to 5
X 10' cells are seeded and Eagle's MEM medium supplemented with low concentration of FBS is changed every 2-3 days. Cell counts are determined every 2-3 days using a Bürkertürk hemocytometer.
〔口〕 発明の構成
本発明は、前記の評価法をもとに強力な作用が確認され
た、次の条件下にある、水溶性蛋白からなる抽出物を含
有する化粧料にある。[Mouth] Structure of the Invention The present invention resides in a cosmetic containing an extract consisting of water-soluble protein under the following conditions, which has been confirmed to have a strong effect based on the above-mentioned evaluation method.
(1)牛の血液から得られた分子量が、75,000、
(等電点:6.0〜6.5付近)(2)牛の乳房から得
られた分子量が、55.000と9.900 (停電点
:前者は6.0〜6.5付近、後者は7.0〜7.5付
近)
(3)牛の肺臓から得られた分子量が、41,000、
(停電点:6.0〜6.5付近)(4)牛の胸腺から得
られた分子量が、46,000、(導電点:6.0〜6
.5付近)但し、上記(1)〜(4)で示きれる水溶性
抽出物は、有機溶媒、強酸、強アルカリ、酵素を用いな
いで、さらに力U熱処理をしない方法で抽出されたもの
に限定されるが、化粧料に用いるに当っては、(1)〜
(4)で示される蛋白は、とくに単離されたものを用い
ることには限定きれず、(1)〜(4)のいず札かを含
む溶液、あるいは、(1)〜(4)のいずれかの粗抽出
液、あるいは、(1)〜(4)のいずれかの抽出物に、
他の安定化剤、その他の各種の剤を用いた溶液としたも
のを、化粧料に含有移せて用いることが出来る。(1) The molecular weight obtained from cow blood is 75,000,
(Isoelectric point: around 6.0 to 6.5) (2) The molecular weights obtained from the cow's udder are 55.000 and 9.900 (blackout point: the former is around 6.0 to 6.5, the latter is around 7.0 to 7.5) (3) The molecular weight obtained from cow lung is 41,000,
(Power failure point: around 6.0 to 6.5) (4) The molecular weight obtained from the cow thymus was 46,000, (conductivity point: 6.0 to 6.
.. 5) However, the water-soluble extracts shown in (1) to (4) above are limited to those extracted by methods that do not use organic solvents, strong acids, strong alkalis, or enzymes, and do not undergo heat treatment. However, when used in cosmetics, (1) ~
The protein shown in (4) is not limited to the use of isolated proteins, but can be used in solutions containing any of (1) to (4), or in solutions containing any of (1) to (4). In any of the crude extracts or in any of the extracts (1) to (4),
A solution containing other stabilizers and various other agents can be incorporated into cosmetics and used.
以下に、さらに具体的に示すために、本発明において特
定した、それぞれの抽出物の製造法、及び、化粧品への
配合(処方)化法を示す。Below, in order to show more concretely, the method for producing each extract specified in the present invention and the method for blending (formulating) it into cosmetics will be shown.
r製造法(抽出法)における要点」
本発明に用いる抽出物の製造法の要点は、次の(イ)〜
(ロ)のごとくである。r Key points in the production method (extraction method)" The key points in the method for producing the extract used in the present invention are as follows (a) -
(b).
(イ )
出発原料は、先に(1)〜(4)で示すものであって、
いずれも屠殺解体処理後の新鮮な臓器を用いることが良
く、通常は凍結保存、又は低温下で保存しておき、適時
用いる二七が良い、尚、血液については、新鮮なバロメ
ーターとして、静置後における状態が、血清と血ペイが
分離状態にあるものの他、分離状態が得られない、溶血
状態にある血清の両方が用いることが可能である。(a) The starting materials are those shown in (1) to (4) above,
In both cases, it is best to use fresh organs after slaughter and dissection, and it is usually best to freeze or store them at low temperatures and use them at appropriate times.As for blood, it is better to leave it still as a fresh barometer. It is possible to use both a state in which the serum and blood are separated, and a state in which the serum is in a hemolyzed state in which no separation is obtained.
(ロ)
抽出に当っての要点は、熱を加えないこと、有m溶媒、
強酸、強アルカリ、酵素を用いないで抽出することが必
須である。(b) The key points in extraction are not to apply heat, to use muffled solvents,
It is essential to extract without using strong acids, strong alkalis, or enzymes.
すなわち、これらの処理操作は、本発明の目的となす、
活性を失活浮せることとなるからである。つまり、従来
、化粧品に配合されてきた動物由来の臓器、又は血液か
ら抽出諮れた、水溶性蛋白等を含むエキス類は、少なく
とも、前述のいずれかの操作が加えられて、最終的に得
られた抽出物を用いてきたが、このような処理を工程中
に採用して得られた抽出物は、細胞に対して直接的に増
殖能を示きなくなることである。That is, these processing operations are the object of the present invention.
This is because the activity will be deactivated. In other words, extracts containing water-soluble proteins extracted from animal-derived organs or blood that have been conventionally blended into cosmetics have been subjected to at least one of the above-mentioned operations before being finally obtained. However, extracts obtained by employing such treatments during the process no longer exhibit the ability to directly proliferate cells.
したがって、これにしたがえば、塩析分画法、ゲル濾過
法、遠心分離法等、従来の生体成分を抽出する方法を組
合せることによって、製造(抽出)が可読である0本発
明者らは、種々の抽出法をもとに得られた抽出物と、活
性作用との関係を追求し、その結果、臓器ごとに主役を
演する活性物質が異なることを見出した。すなわち、得
られた抽出物の主役物質は、水溶性の蛋白であるが、分
子量が異なっていることが、前記で示す評価試験によっ
て確認されたのである。Therefore, according to this, by combining conventional methods for extracting biological components such as salting-out fractionation method, gel filtration method, centrifugation method, etc., the production (extraction) can be read. investigated the relationship between extracts obtained using various extraction methods and their active effects, and as a result found that the active substances that play a leading role differ depending on the organ. That is, although the main substance of the obtained extract is a water-soluble protein, it was confirmed by the evaluation test shown above that the molecular weight is different.
つまり、加熱処理、有機溶媒処理、強酸及び強アルカリ
処理、酵素分解処理を加えない抽出条件下で得られた抽
出エキス(粗液)中には、どの臓器又は血液中にも、作
用の強弱はあっても、いずれにも、細胞増殖能を有する
水溶性蛋白が存在することがわかった。そして、さらに
得られた抽出エキスをもとに、その粗液(抽出エキス)
の主役物質の単離(分離)精製化を行った結果、先に(
1)〜(4)で示したごとくの分子量をもった物質であ
ることが確認出来たのである。In other words, the extract (crude liquid) obtained under extraction conditions without heat treatment, organic solvent treatment, strong acid/alkaline treatment, or enzymatic decomposition treatment has no effect on any organ or blood. However, it was found that all of them contain water-soluble proteins that have the ability to proliferate cells. Then, based on the extracted extract obtained, the crude liquid (extract)
As a result of isolation (separation) and purification of the main substance of (
It was confirmed that the substance had the molecular weight shown in 1) to (4).
したがって、主役作用物質が発見出来たことにより、抽
出法は、いろいろの公知手段をもとに、その組合せを工
夫すれば、以下に記す、本発明者らの方法にこだわるこ
となく、目的となす有効物質の抽出が可能となつたので
ある。Therefore, with the discovery of the main active substance, extraction methods can be used to achieve the objectives described below by devising combinations of them based on various known means, without being limited to the method of the present inventors. It became possible to extract effective substances.
「抽出例−1=血液、血清からの抽出法」牛の血液(溶
血したものも可)、又は血液から分離して得られた血清
を、20%飽和の濃度になるように、硫酸アンモニウム
を添加後、遠心分離して、上清液を分取し、この上清液
に対して、60%飽和の濃度になるように、再び硫酸ア
ンモニウムを添加し、遠心分離して沈殿物を回収する。"Extraction example-1 = Extraction method from blood and serum" Ammonium sulfate is added to bovine blood (hemolyzed blood is also acceptable) or serum obtained by separating it from blood to a 20% saturation concentration. Thereafter, the supernatant is separated by centrifugation, ammonium sulfate is added again to the supernatant to a concentration of 60% saturation, and the precipitate is recovered by centrifugation.
次に、沈殿物は、少量の水又は生理食塩水等に溶解した
後、脱塩操作を行う、脱塩操作は、ゲル濾過、限外濾過
、透析などのいずれの方法でもよいが、ここでは例えば
、透析チューブに入れて、充分量の生理食塩水等により
、−昼夜以上透析する方法を採用して、分子量が75.
000を有する、水溶性蛋白を含む液体(粗液)を得た
。Next, the precipitate is dissolved in a small amount of water or physiological saline, and then desalted. The desalting operation may be performed by any method such as gel filtration, ultrafiltration, or dialysis. For example, if a method is adopted in which the molecular weight is 75.
A liquid (crude liquid) containing a water-soluble protein having a molecular weight of 0.000 was obtained.
1抽出例−2:乳房からの抽出法」
牛の乳房を洗浄することなく細切し、低温下でホモジナ
イザー等でホモジナイズした後、水又は塩化ナトリウム
溶液又は、第1表に示すごとくの緩衝液を添加して、攪
拌する。ここでは、水又は塩化ナトリウム溶液を添加し
て攪拌した後、6時間〜−昼夜放置した後、遠心分離し
て上清液を得て、この上清液に対して40%飽和の濃度
になるように、硫酸アンモニウムを添加し、遠心分離し
て、その上清液を取り、上演液に対して、80%飽和の
濃度になるように、再度、硫酸アンモニウムを添加し、
遠心分離してその沈殿物を回収する、以下の操作は、前
記抽出例1に示すと同様に、少量の水、又は生理食塩水
等に溶解した後、脱塩操作を行うことによって、分子量
が55.000と9.900にある水溶性蛋白を含む液
体(粗液)を得ることができる。1 Extraction Example-2: Extraction method from udder Cut the cow's udder into small pieces without washing, homogenize with a homogenizer or the like at low temperature, and then add water or sodium chloride solution, or a buffer solution as shown in Table 1. Add and stir. Here, after adding water or a sodium chloride solution and stirring, it is left to stand for 6 hours - day and night, and then centrifuged to obtain a supernatant, which has a concentration of 40% saturation with respect to this supernatant. Add ammonium sulfate, centrifuge, take the supernatant, add ammonium sulfate again to the stage solution to a concentration of 80% saturation,
The following operation of collecting the precipitate by centrifugation is similar to that shown in Extraction Example 1 above, by dissolving it in a small amount of water or physiological saline, etc., and then desalting it to reduce the molecular weight. A liquid (crude liquid) containing water-soluble proteins at 55.000 and 9.900 can be obtained.
「抽出例−3:肺臓からの抽出法j
牛の肺臓を洗浄などの前処理を行わないで細切した後、
低温下でホモジナイズする。ホモジナイズした後、水又
は塩化ナトリウム溶液、あるいは第1表に示すごとくの
緩衝液を添加し、以後の操作は、前記抽出例2に準拠し
て行うとよい、但し、その際に、第2回目の硫酸アンモ
ニウムを添加する操作に当っては、60%飽和の濃度に
なるように調整する。これによって、分子量が41゜0
00を有する、水溶性蛋白を含む液体(粗液)が得られ
る。“Extraction Example-3: Extraction method from lungs j After cutting cow lungs into small pieces without performing any pretreatment such as washing,
Homogenize at low temperature. After homogenization, water or sodium chloride solution, or a buffer as shown in Table 1 is added, and the subsequent operations are preferably carried out in accordance with Extraction Example 2 above.However, in this case, the second When adding ammonium sulfate, the concentration is adjusted to 60% saturation. This results in a molecular weight of 41°0
A liquid containing water-soluble protein (crude liquid) having a pH of 0.00 is obtained.
1抽出例−4:胸腺からの抽出法j
牛の胸腺を洗浄などの前処理をしないで、直ちに細切し
、低温下でホモジナイズする。以後の操作は、前記抽出
例3と同様の操作を行う、これによって、分子量が46
.000を有する、水溶性蛋白を含む液体(粗液)が得
られる。1 Extraction Example-4: Extraction method from thymus j Cow thymus is immediately cut into pieces without pretreatment such as washing, and homogenized at low temperature. The subsequent operations are the same as those in Extraction Example 3. As a result, the molecular weight is 46.
.. A liquid containing a water-soluble protein (crude liquid) having a molecular weight of 0.000 is obtained.
「第1表」
粗抽出における緩衝液と精製におけるイオン交換体との
関係前記抽出例1〜4で示した方法によって得られた抽
出液(粗液)は、そのまま本発明が目的とする化粧料に
配合して用いることも出来るものであって、細胞に対し
て、直接に増殖能を示す、すなわも、肌に対してこれを
配合して用いれば、皮膚組繊細胞の代謝を円滑となし、
老化防止効果を発揮して、小シワを防ぎ、艶のある若々
しい肌を形成してくれるようになる。又、肌に小きな切
傷などのある場合、あるいは、妊産婦(産前産後)の顔
面のシミが強くわかるようになった場合、あるいは、肝
斑などに対しては、これらのシミの色素沈着を少なく防
ぐことが出来る。"Table 1" Relationship between buffer solution in crude extraction and ion exchanger in purification The extract (crude solution) obtained by the method shown in Extraction Examples 1 to 4 above can be used as it is in the cosmetics targeted by the present invention. It can also be used in combination with the skin, and it shows direct proliferation ability for cells.In other words, if it is used in combination with the skin, it can smooth the metabolism of skin tissue cells. none,
It has anti-aging effects, prevents fine wrinkles, and gives you shiny, youthful skin. In addition, if there are small cuts on the skin, or if spots on the face of pregnant women (before and after childbirth) become noticeable, or if you have melasma, please check the pigmentation of these spots. It can be prevented to a minimum.
又、きらに、主役を演する、それぞれの物質(特定され
た分子量を有する蛋白)を精製して用いることも良いが
、その精製化法は、例えば、前記抽出例1〜4で得られ
た粗液を、公知なゲル濾過、イオンクロマト等を組合せ
ることにより、分画することによって精製できる。又、
ゲル濾過に用いられる担体としては、セファデックス、
アガロース、セファクリル等が上げられる。In addition, it is also good to purify and use each substance (protein with a specified molecular weight) that plays a leading role, but the purification method is, for example, the one obtained in Extraction Examples 1 to 4 above. The crude liquid can be purified by fractionation using a combination of known gel filtration, ion chromatography, and the like. or,
Carriers used for gel filtration include Sephadex,
Examples include agarose and sephacryl.
1精製化例−1ノ
前記抽出例1〜4で得られた、それぞれの粗液について
、次に示す〔1〕の条件下で処理し、目的とする活性フ
ラクシヨンを、さらに〔2〕で示すイオン交換体(m脂
)によって分画する。イオン交換に用いる担体としては
、セファデックス、セファロース、セファクリル等の陽
・陰イオン交換体等が上げられるが、ここでは、例えば
DEAB−セファロースCL−6Bを用いて行った。1 Purification Example - 1 Each of the crude liquids obtained in Extraction Examples 1 to 4 was treated under the conditions of [1] shown below, and the desired active fraction was further obtained as shown in [2]. Fractionation is performed using an ion exchanger (m fat). Examples of carriers used for ion exchange include cationic and anionic exchangers such as Sephadex, Sepharose, and Sephacryl. Here, for example, DEAB-Sepharose CL-6B was used.
〔1〕
樹脂:セファクリル S−200スーパーフアイン、カ
ラムサイズ:26X956+1111%溶媒二0.1M
−0,05Nトリス塩酸バツフアーCpH8,0)、流
速: 3 、3 mfi/Il″m ”/ h〔2〕
樹脂:DEAE−セファロースCL−6B、溶媒:0.
IM−0,05Nトリス塩酸バツフアー(pH8,0)
、溶出条件:NaC1m度0−0.3M上記〔2〕によ
って得られた活性フラクションを、さらにセファクリル
S−200でゲル濾過し、これによって、特定されたそ
れぞれの分子量を有する、水溶性の活性フラクションを
分取する。[1] Resin: Sephacryl S-200 Super Fine, column size: 26X956+1111% solvent 20.1M
-0,05N Tris-HCl buffer CpH 8,0), flow rate: 3,3 mfi/Il″m″/h [2] Resin: DEAE-Sepharose CL-6B, solvent: 0.
IM-0,05N Tris-HCl buffer (pH 8,0)
, Elution conditions: NaC 1m degree 0-0.3M The active fraction obtained in the above [2] was further gel-filtered with Sephacryl S-200, thereby obtaining water-soluble active fractions having the respective specified molecular weights. Separate.
上記の精製化後の分離された、特定の分子量で示される
抽出物の活性(細胞増殖能)は、それぞれ、第2〜1図
に示すごとくである。The activities (cell proliferation ability) of the extracts separated after the above purification and indicated by specific molecular weights are as shown in FIGS. 2 to 1, respectively.
すなわち、第1図は、5%FBS(牛胎児血清)の濃度
による、細胞増殖曲線を示したものであるが、これと対
比するとき、そのいずれの抽出物も強い活性を示してい
ることである。In other words, Fig. 1 shows cell growth curves depending on the concentration of 5% FBS (fetal bovine serum), and when compared with this, all extracts show strong activity. be.
このような作用は、従来の抽出法によるエキスとして、
仮に同様な分子量にある成分が含まれていたエキスであ
るとしても、
ミミ失活されたエキスとなっていたことである。This effect is achieved by extracts obtained using conventional extraction methods.
Even if the extract contained components with similar molecular weights, it would have been an extract that had been deactivated.
′ したがって、従来法における抽出物について、対比
するための表や図などをもって、その結果は示していな
いが、この原因については徹底的に追求を行った。'Therefore, we have thoroughly investigated the cause of this problem, although we do not show the results of the extracts obtained using the conventional method, with tables and figures for comparison.
その結果、細胞増殖能を有する活性物質は、次の条件に
触れると、失活されることである。As a result, active substances capable of cell proliferation are inactivated when exposed to the following conditions.
(1)体温以上の加温下にあっては、特別な条件以外で
、長時間さらされるとき、(2)有機溶媒中にさらされ
るとき、(3)強酸、強アルカリ、蛋白分解酵素の存在
下にきらきれるとき、これらの処理をもって抽出された
エキス類は、そのほとんどが、amに対して、もはや増
殖能を示さず、活性のないエキスとなってしまうことが
わかったのである。(1) When exposed to heat above body temperature for a long time under special conditions, (2) When exposed to organic solvents, (3) In the presence of strong acids, strong alkalis, or proteolytic enzymes. However, it was found that most of the extracts extracted through these treatments no longer show proliferative ability against am and become inactive extracts.
つまり、従来の医薬や化粧料に用いられてきたところの
、各種の動物由来の、臓器から抽出されたところのエキ
スは、少なくとも、上記の処理の一つを工程中で採用し
、言らには、抗菌性薬剤(防腐、防パイ剤等)を用い、
あるいは原料を用いるに当り、脱血、脱血等の処理を加
え、抽出されたものが用いられてきた。ところが、これ
らの操作を加えることによっても、目的とする活性物質
は、急速に失活されてしまうこととなる。とくに、前処
理での水洗は、主役活性物質の流出をまねき、その結果
は、どれだけ蛋白量が多い水溶性抽出物を得ても、まっ
たく作用のないエキスとなる。又、抗菌剤は、これ自体
が、細胞に対しては、毒物であることは言うまでもなく
、作用を求めることが出来ないわけである。有機溶媒の
処理も同様である。ましてや、酵素を用いたり、強厳、
強アルカリは、活性物質に対して、即、変性分解し失活
きれてしまうことがわかったのである。In other words, extracts extracted from organs derived from various animals, which have been used in conventional medicines and cosmetics, are processed by applying at least one of the above treatments during the process. uses antibacterial agents (preservatives, anti-inflammatory agents, etc.),
Alternatively, when using the raw material, it has been extracted after undergoing treatments such as blood removal and blood removal. However, even with these operations, the desired active substance is rapidly deactivated. In particular, washing with water during pretreatment causes the main active substance to flow out, and the result is an extract that has no effect at all, no matter how high the protein content of the water-soluble extract. Furthermore, it goes without saying that antibacterial agents themselves are toxic to cells, and cannot be expected to have any effect on cells. The same applies to the treatment of organic solvents. Moreover, using enzymes,
It was discovered that strong alkalis immediately denature and decompose active substances, deactivating them.
したがって、これらの従来の方法を用いて得られた抽出
物は、肌に対して保湿性能は顕著であっても、古来から
伝えられてきた、細胞や組織代謝を促進する作用が知ら
れながらも、その効果については、少ないものであった
か、あるいは、栄養剤的な二次的効果から得られたもの
であると考えられるに至った。Therefore, although extracts obtained using these conventional methods have a remarkable moisturizing effect on the skin, they are known to have the effect of promoting cell and tissue metabolism, which has been reported since ancient times. It has come to be believed that the effect was small, or that it was obtained from a secondary effect as a nutritional supplement.
「製剤化法の要点」
次に、本発明による化粧料への利用に関して述べると、
化粧料への配合に当っては、従来の各種動物由来の抽出
物と同様にして用いることが出来るが、しかし、前記し
たごとく、抽出法における操作上、失活の原因として上
げたような物質などとの処方化は、極力避けることが望
ましい、又、クリームや乳液の製剤化に当っては、極力
加熱処理を避けることが望ましい。"Key Points of Formulation Method" Next, we will discuss the use of the present invention in cosmetics.
When blended into cosmetics, it can be used in the same manner as conventional extracts derived from various animals, but as mentioned above, due to the extraction method, the substances listed as causes of deactivation may be used. It is desirable to avoid formulating creams and emulsions as much as possible, and it is also desirable to avoid heat treatment as much as possible when formulating creams and emulsions.
化粧水などの液状タイプの化粧品類で、乳化又は懸濁化
を必要としない製品に配合するに当っては、はとんど加
熱処理を必要としない場合が多く、失活きれることはな
い、したがって、作用は安定に持続される、しかし、さ
らに長期間にわたり、本発明に示す活性物質(抽出物)
を含有する化粧品類の処方化に当っては、たとえば、従
来法による、各種の動物由来の加水分解や、有機溶媒等
の処理によって得られた、水溶性の蒼白、ペプチド、ア
ミノ酸等を含む抽出物(エキス)、あるイハ、ムコ多糖
類(ヒアルロン酸、フンドロイチン硫酸など)及び、そ
れらを含むエキス類、キトサン又はキチンの水溶化物な
どとの併用は、安定性の持続性を向上することとなる。When incorporated into liquid cosmetics such as lotions that do not require emulsification or suspension, heat treatment is often not required, and the product will not be deactivated. Therefore, the action is stably sustained, but the active substance (extract) shown in the present invention can be used for a longer period of time.
When formulating cosmetics containing , for example, extracts containing water-soluble pallor, peptides, amino acids, etc. obtained by hydrolysis of various animal-derived materials or treatment with organic solvents, etc., using conventional methods. The concomitant use with substances (extracts), certain Iha, mucopolysaccharides (hyaluronic acid, fundroitin sulfate, etc.), extracts containing them, aqueous solutions of chitosan or chitin, etc. will improve the sustainability of stability. .
又、これらの既知の物質(抽出物)は、化粧水などの液
状タイプの、乳化や懸瀾を必要としない製品のみならず
、クリームや乳液などの処方中に併用しても、同様の成
績が得られる。In addition, these known substances (extracts) can be used not only in liquid products such as lotions that do not require emulsification or suspension, but also when used in the formulation of creams and emulsions with similar results. is obtained.
したがって、本発明においては、たとえば、抽出例1〜
4で示す、粗液を抽出した後の残渣物を用い、この残漬
物を、公知な加水分解(強酸、強アルカリ、酵素などに
よる分解)や、有機溶媒を用いて抽出されたエキスを得
て、これを安定化剤として用いても良い、もちろん、こ
の残渣物から得られた抽出エキスは、肌に対する保湿性
に優れた効果を発揮する。但し、細胞に対する増殖能は
ゼロである。Therefore, in the present invention, for example, extraction examples 1 to
Using the residue after extracting the crude liquid shown in 4, this residual pickle is subjected to known hydrolysis (decomposition with strong acid, strong alkali, enzyme, etc.) or an extract extracted using an organic solvent. This may also be used as a stabilizer. Of course, the extract obtained from this residue exhibits excellent moisturizing effects on the skin. However, the ability to proliferate cells is zero.
1処方例−1=化粧水タイプの剤」
■抽出側1〜4で得られた粗液、又は、■その粗液を適
当な濃度に減圧下で濃縮した液、又は、■粗液から得ら
れた精製後の凍結乾燥粉末を、次の処方中に添加し、常
法により化粧水を製す。1 Prescription Example - 1 = Lotion type agent" ■ The crude liquid obtained in extraction side 1 to 4, or ■ A liquid obtained by concentrating the crude liquid under reduced pressure to an appropriate concentration, or ■ Obtained from the crude liquid. The purified freeze-dried powder is added to the next formulation to produce a lotion using a conventional method.
■では1〜20%、■では0.3〜0.5%、■では0
.001〜0.1%を、以下の処方中に加える。1-20% for ■, 0.3-0.5% for ■, 0 for ■
.. 001-0.1% is added in the following formulation.
カルボキシメチルキチン含有水溶液・・・・20%プロ
ピレングリフール・・・・・・・・・・・・・・・・・
・3%ブラセナンドV(プラセンターエキス)・・5%
精製水をもって全量100となす。Aqueous solution containing carboxymethyl chitin...20% propylene glyfur...
・3% Brasenando V (place center extract)...5%
Make total volume 100 with purified water.
1処方例−2:ミルクローションタイプの剤」あらかじ
め、前記処方例1で示す■を501カルボキシメチルキ
チン含有水溶涜20.ヒアルロン酸ナトリウム0.3%
を含む水溶液、又はR5Cリキッド(鶏冠抽出ムフ多糖
体含有水溶液)20、抽出例1〜4のいずれかの粗液を
抽出する際に出た残渣物を、公知な加水分解をして得ら
れた、水溶性の蛋白質由来の抽出物を含有する溶液(総
窒素量300w/v%含有)10の割合で混和した水溶
液を作っておき、以下の処方中に、5〜20%添加(処
方中の温度が45℃以下になった頃、少量ずつ添加)し
て製する。1. Prescription Example-2: Milk Lotion Type Agent" In advance, prepare 20. Sodium hyaluronate 0.3%
or R5C Liquid (cock's comb extracted mufu polysaccharide-containing aqueous solution) 20, the residue produced when extracting the crude liquid of any of Extraction Examples 1 to 4 was obtained by known hydrolysis. , an aqueous solution containing a water-soluble protein-derived extract (containing a total nitrogen content of 300 w/v%) is prepared in advance, and added to the following formulation by 5 to 20% (containing a total nitrogen content of 300 w/v%). When the temperature drops below 45℃, add it little by little).
流動パラフィン・・・・・・・・・・・・・・・・・・
・・・・13%スクワラン・・・・・・・・・・・・・
・・・・・・・・・・・・・10%ステアリン酸・・・
・・・・・・・・・・・・・・・・・・・・・15%ラ
ノリン・・・・・・・・・・・・・・・・・・・・・・
・・・・・・・・4%サラシミツロウ・・・・・・・・
・・・・・・・・・・・・・・・・2%トリオレイン酸
ソルビタン・・・・・・・・・・・・・・2%卵黄レシ
チン(総リン脂質として99%)・・2%パラベン(3
種複合)・・・・・・・・・・・・・・・・適 量香料
・・・・・・・・・・・・・・・・・・・・・・・・・
・・・・・・・適 置端製水をもって全量100となす
。Liquid paraffin・・・・・・・・・・・・・・・・・・
・・・13% squalane・・・・・・・・・・・・・・・
・・・・・・・・・・・・10% stearic acid...
・・・・・・・・・・・・・・・・・・15% Lanolin・・・・・・・・・・・・・・・・・・・
・・・・・・・・・4% white beeswax・・・・・・・・・
・・・・・・・・・・・・・・・2% sorbitan trioleate ・2% egg yolk lecithin (99% as total phospholipids) 2% paraben (3
Seed complex)・・・・・・・・・・・・・・・・・・Appropriate amount Fragrance・・・・・・・・・・・・・・・・・・・・・・・・・
......Appropriately, make the total amount 100 with the water at the end.
〔ハ〕 発明の効果
本発明によって得られた、それぞれの抽出物は、直接に
細胞増殖能を有するものであることは、先の評価法によ
る試験によって開示したごとくである。このような活性
作用を有する抽出物を含有する化粧料は、例えば切傷、
火傷等における表皮層から真皮層に至る損傷に対し、そ
の急速な修復作用に働くこととなって、その損傷局所に
対して、再生を促進する効果が得られる。したがって、
化粧料分野のみならず、医療用外用剤としても、用いる
ことが出来る。いずれに用いる場合にも、抽出物は抽出
処理工程において、最終的には、完全な除菌操作を必要
とする。[C] Effects of the Invention It has been disclosed by the test using the above evaluation method that each extract obtained by the present invention has the ability to directly proliferate cells. Cosmetics containing extracts with such active effects can be used, for example, to treat cuts,
It works to rapidly repair damage from the epidermal layer to the dermal layer due to burns, etc., and has the effect of promoting regeneration in the damaged area. therefore,
It can be used not only in the cosmetics field but also as a medical external preparation. In either case, the extract requires complete sterilization in the extraction process.
化粧品への利用(配合)による効果は、肌の老化を紡ぐ
ことにある。すなわち、肌の老化は、表皮層部の乾燥、
シワの増加、艶の低下、シミの発生などが外観的にみら
れることとなる。これを真皮層から観察すれば、線維芽
細胞の代謝機能の低下が上げられる。つまり、線維芽細
胞は、それを取りまく、組織線維(コラーゲンなど)の
再生と共に、その組織線維間の水溶液物質の保持に働く
細胞であり、ムコ多糖体等のバランス維持にも深く係わ
るものであるが、この活動が低下している為に起きるこ
とが、大きな原因の一つとなると考えることが出来るわ
けである。The effect of its use (compounding) in cosmetics is to counteract skin aging. In other words, skin aging is caused by dryness of the epidermal layer,
Increased wrinkles, decreased luster, and appearance of stains can be seen in appearance. If this is observed from the dermal layer, it can be seen that the metabolic function of fibroblasts has decreased. In other words, fibroblasts are cells that work to regenerate surrounding tissue fibers (such as collagen) and maintain aqueous substances between the tissue fibers, and are deeply involved in maintaining the balance of mucopolysaccharides, etc. However, it can be thought that one of the major causes is that this activity is reduced.
このことについては、例えば、本発明者らは1、am芽
細胞に対して、直接に増殖作用を有する前記の抽出液(
粗液)を投与することによって、これと共に、ムコ多糖
体の生成、水溶性コラーゲンの生成能が高まる状態を、
顕微鏡下で確認することが出来たのである。Regarding this matter, for example, the present inventors have investigated 1.
By administering crude liquid), a state in which mucopolysaccharide production and water-soluble collagen production ability are increased.
This could be confirmed under a microscope.
したがって、化粧品中に含有菌せて用いれば、徐々に肌
に滲透されて、肌を若々しく保つことが可能となる。と
くに従来から、いろいろの動物超厚の臓器から抽出され
たエキスが、化粧品中に配合きれ、少なからず、細胞や
組織賦活能を期待きれて用いられてきた歴史的経緯をも
ってすれば、本発明による抽出物の利用は、その作M機
序に対して、より具体的な細胞レベルにおける評価法を
採用して、効果を裏付けるに至ったことは、今後の化粧
品類の開発にとっても、大きな進歩をもたらすものであ
ると考えている。Therefore, if the bacteria are used in cosmetics, they will gradually penetrate into the skin, making it possible to keep the skin youthful. In particular, given the historical background in which extracts extracted from the extremely thick organs of various animals have been incorporated into cosmetics and have been used with high expectations for their ability to activate cells and tissues, the present invention The use of extracts has been able to confirm its effectiveness by adopting a more specific evaluation method at the cellular level for its M production mechanism, which will be a major advance for the future development of cosmetics. I think that it will bring.
第1rXJは、FBS(牛胎児血清)を5%含有する溶
液が示す細胞増殖能を示す。
第2〜6図は、本発明によって得られた水溶性蛋白の有
する細胞増殖能を示す。
第2図は、牛の血清(血液)由来の水溶性蛋白(分子量
: 75.000 )、第3図は、牛の乳房由来の水溶
性蛋白(分子量、55.0OO)、第4図は、牛の乳房
由来の水溶性蛋白(分子量:9.900 )、第5図は
、牛の脾臓由来の水溶性蛋白(分子量:41.0OO)
、第6図は、牛の胸腺由来の水溶性蛋白(分子量:46
.0OO)。
第2〜6図中、イは添加量が1μg / ml)におけ
る増殖曲線、口は添加量が0.1μg/−における増殖
曲線、ハは対照群の増殖曲線。
t21i1ii
Lo 。
j8I!日数
培養日数
図面
!s3図
培養日数
!0
181118股The first rXJ shows the cell proliferation ability of a solution containing 5% FBS (fetal bovine serum). Figures 2 to 6 show the cell proliferation ability of the water-soluble protein obtained by the present invention. Figure 2 shows water-soluble protein derived from cow serum (blood) (molecular weight: 75.000), Figure 3 shows water-soluble protein derived from cow udder (molecular weight, 55.0OO), and Figure 4 shows: Water-soluble protein derived from cow udder (molecular weight: 9.900), Figure 5 shows water-soluble protein derived from cow spleen (molecular weight: 41.0OO)
, Figure 6 shows water-soluble protein derived from bovine thymus (molecular weight: 46
.. 0OO). In Figures 2 to 6, A shows the growth curve when the added amount is 1 μg/ml), H shows the growth curve when the added amount is 0.1 μg/ml, and C shows the growth curve of the control group. t21i1ii Lo. j8I! Number of days for cultivation! s3 diagram culture days! 0 181118 legs
Claims (1)
いで抽出された牛の血液又は牛の臓器由来の水溶性蛋白
を含有してなる化粧料にあって、その含有する水溶性蛋
白の分子量、及び等電点が、次に示す(1):牛の血清
由来の抽出物では、75,000、その等電点が6.0
〜6.5付近、(2):牛の乳房由来の抽出物では、5
5,000と9,900、その等電点が、前者では6,
0〜6.5付近、後者では7.0〜7.5付近、(3)
:牛の脾臓由来の抽出物では、41,000、その等電
点が6.0〜6.5付近、(4):牛の胸腺由来の抽出
物では、46,000、その等電点が6.0〜6.5付
近である、その(1)〜(4)の1種、又は1種以上を
含有することを特徴とする化粧料。Cosmetics containing water-soluble proteins derived from cow blood or cow organs extracted without using organic solvents, strong acids, strong alkalis, or enzymes and without heating, the molecular weight of the water-soluble proteins contained therein. , and isoelectric point are as follows (1): 75,000 for extract derived from bovine serum, and its isoelectric point is 6.0.
- Around 6.5, (2): For extracts derived from cow udder, 5
5,000 and 9,900, their isoelectric points are 6,
Around 0 to 6.5, the latter around 7.0 to 7.5, (3)
: Extract derived from bovine spleen has a concentration of 41,000 and its isoelectric point is around 6.0 to 6.5. 6.0 to about 6.5, and contains one or more of (1) to (4).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1908787A JPS63188607A (en) | 1987-01-29 | 1987-01-29 | Cosmetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1908787A JPS63188607A (en) | 1987-01-29 | 1987-01-29 | Cosmetic |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63188607A true JPS63188607A (en) | 1988-08-04 |
Family
ID=11989672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1908787A Pending JPS63188607A (en) | 1987-01-29 | 1987-01-29 | Cosmetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63188607A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9069151B2 (en) | 2011-10-26 | 2015-06-30 | Corning Cable Systems Llc | Composite cable breakout assembly |
-
1987
- 1987-01-29 JP JP1908787A patent/JPS63188607A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9069151B2 (en) | 2011-10-26 | 2015-06-30 | Corning Cable Systems Llc | Composite cable breakout assembly |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL187989B1 (en) | Shark cartilage extracts, method of obtaining such extracts and compositions containing them | |
EP0140134B1 (en) | Process for the preparation of a biologically active extract | |
HUE024101T2 (en) | Extracellular yaluronidase from streptomyces koganeiensis | |
JPS6028999A (en) | Protein having cell proliferation accelerating action, its composition and its preparation | |
JP6117456B1 (en) | Wrinkle improving composition containing placenta-derived component | |
EP1908455A1 (en) | Hair care preparation | |
KR20130048164A (en) | Jellyfish collagen peptide mixture | |
CN105420325A (en) | Placenta polypeptide preparation method | |
Dahl et al. | Chemokinetic and chemotactic factors in psoriasis scale extracts | |
JPS6354001B2 (en) | ||
WO2018207810A1 (en) | Method for producing amnion-derived raw material, method for producing cosmetic, and method for producing health food | |
JP2572931B2 (en) | Whitening agent | |
DE3780047T2 (en) | USE OF BIOLOGICALLY ACTIVE POLYPEPTIDES AND COMPOSITIONS CONTAINING THEM. | |
JPS63188607A (en) | Cosmetic | |
US7429561B2 (en) | Method for stimulating cell growth using sponge protein hydrolysates | |
JP2533376B2 (en) | Skin cosmetics | |
JPS62116519A (en) | Cell metabolism activating substance extracted from placenta, extraction thereof and method for inactivating hepatitis virus | |
RU2610669C1 (en) | Method for production of proteolytic preparation for medical use | |
JPH0426604A (en) | Cosmetic and dermatic drug for external use | |
JP2014058459A (en) | Method of producing collagen production facilitating suspension | |
RU2241474C1 (en) | Placental preparation and methods for its obtaining | |
JPH01115903A (en) | Production of hyaluronic acid | |
DE69230887T2 (en) | PROTEOLYTIC MIXTURE CONTAINING ESCHARASE AND METHOD OF ITS INSULATION | |
JPH0717844A (en) | Cosmetic composition | |
JPH08143445A (en) | Cosmetic |